>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • LRN +25.8%, TMHC +5.9%, ENVA +5.5%, JBT +5%, NTRS +4.5%, WPP +4.4%, VBTX +4.2%, EVR +3.8%, VICR +3.6%, TXN +3.5%, WFRD +3.4%, T +3%, PKG +2.9%, LII +2.9%, BPOP +2.1%, PB +2%, VLRS +1.7%, RRC +1.2%, TRU +1.2%, BSX +1.1%, TNL +1%
Other news:
  • SEIC +5% (increases buyback authorization by $400 mln)
  • ORIC +4.9% (presents data further supporting potential best-in-class profile of ORIC-114 to treat EGFR Exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics)
  • RPTX +3.7% (presents updated data highlighting the benefits of its individualized schedule for the management of anemia in the Phase 1 MYTHIC clinical trial treating patients with the combination of lunresertib and camonsertib)
  • WEN +3.6% (in sympathy with E. coli outbreak at MCD)
  • DOUG +3.5% (CEO to retire, names new CEO)
  • LNZA +3.5% (determined to settle the forward purchase agreement in cash and paid to ACM $7,500,000 in maturity consideration and $2,539,350 in share consideration)
  • COGT +2.9% (announces the addition of a potent and selective KRAS inhibitor to its pipeline)
  • JANX +2.7% (RA Capital disclosed the purchase of 1,200,000 shares in a private transaction)
  • QSR +2.6% (in sympathy with E. coli outbreak at MCD)
  • CDNA +1.9% (CareDx and Dovetail Genomics announce a strategic partnership to drive the next wave of innovation in HLA genotyping for organ and stem cell transplant matching)
  • RVMD +1.8% (presents updated data from RMC-6236 monotherapy study in patients with advanced pancreatic ductal adenocarcinoma)
  • GLUE +1.7% (announces the company will present preclinical data at the 36th EORTC-NCI-AACR Symposium, on the potential of its cyclin E1-directed molecular glue degraders for the treatment of CCNE1-amplified solid tumors)
  • REFI +1.5% (closes on $50 million unsecured term loan to fund deployment of new investments)
  • MTX +1.3% (expands partnership with AIM Intelligent Machines)
  • SDGR +1.3% (presents SGR-3515 preclinical data at 2024 EORTC-NCI-AACR Symposium)
  • BYON +1% (to reduce workforce by 20%)
Analyst comments:
  • AMLX +8.2% (upgraded to Buy from Neutral at BofA Securities)
  • SNAP +2.4% (upgraded to Mkt Outperform from Mkt Perform at JMP Securities)